Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score
Hematology, Oncology and Stem Cell Therapy. 2016; 9 (2): 48-54
em Inglês
| IMEMR
| ID: emr-182865
ABSTRACT
Objective/Background:
Progesterone-receptor negativity [PR-] is predictive of adverse outcomes in estrogen receptor-positive [ER+] breast cancer. The Oncotype DX assay provides risk stratification for hormone receptor-positive [HR+] invasive breast cancer; however, the association of PR status and Oncotype DX recurrence scores [RSs] is less clear
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Idioma:
Inglês
Revista:
Hematol. Oncol. Stem Cell Ther.
Ano de publicação:
2016
Similares
MEDLINE
...
LILACS
LIS